Dapagliflozin to prevent AF recurrence after ablation
Part of Heart & circulation clinical trials.
This trial tests if dapagliflozin, a medication for diabetes and heart failure, can help prevent atrial fibrillation from returning after your first catheter ablation procedure for AF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have type 2 diabetes or heart failure
- You have atrial fibrillation confirmed by an ECG or Holter monitor
- You are scheduled for your first catheter ablation for atrial fibrillation
- You do not have a urinary tract infection
- You are not pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called dapagliflozin can reduce abnormal electrical activity in the heart by targeting fat around the heart in people with atrial fibrillation who are scheduled for a first catheter ablation. It may help improve the success of the procedure.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
This trial tests if adding dapagliflozin (a diabetes drug) helps control heart rhythm in people recently diagnosed with atrial fibrillation. It's for those who haven't tried rhythm control treatments before.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.